ATE522809T1 - Vegf-polymorphismen und antiangiogenese-therapie - Google Patents

Vegf-polymorphismen und antiangiogenese-therapie

Info

Publication number
ATE522809T1
ATE522809T1 AT08857392T AT08857392T ATE522809T1 AT E522809 T1 ATE522809 T1 AT E522809T1 AT 08857392 T AT08857392 T AT 08857392T AT 08857392 T AT08857392 T AT 08857392T AT E522809 T1 ATE522809 T1 AT E522809T1
Authority
AT
Austria
Prior art keywords
vegf
antiangiogenesis therapy
polymorphisms
patient
therapy
Prior art date
Application number
AT08857392T
Other languages
English (en)
Inventor
Bryan P Schneider
Milan Radovich
George W Sledge
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40347982&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE522809(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE522809T1 publication Critical patent/ATE522809T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G01N33/575—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00—Reactions of nucleic acids characterised by
    • C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/113—PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2561/00—Nucleic acid detection characterised by assay method
    • C12Q2561/101—Taqman
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2561/00—Nucleic acid detection characterised by assay method
    • C12Q2561/113—Real time assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G01N33/57515—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT08857392T 2007-11-30 2008-11-26 Vegf-polymorphismen und antiangiogenese-therapie ATE522809T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99161607P 2007-11-30 2007-11-30
US3869908P 2008-03-21 2008-03-21
PCT/US2008/084933 WO2009073540A2 (en) 2007-11-30 2008-11-26 Vegf polymorphisms and anti-angiogenesis therapy

Publications (1)

Publication Number Publication Date
ATE522809T1 true ATE522809T1 (de) 2011-09-15

Family

ID=40347982

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08857392T ATE522809T1 (de) 2007-11-30 2008-11-26 Vegf-polymorphismen und antiangiogenese-therapie

Country Status (23)

Country Link
US (1) US10031141B2 (de)
EP (2) EP2506010B1 (de)
JP (3) JP2011505145A (de)
KR (2) KR101651796B1 (de)
CN (2) CN102016579B (de)
AT (1) ATE522809T1 (de)
AU (1) AU2008334070B2 (de)
BR (1) BRPI0819018A2 (de)
CA (1) CA2705792A1 (de)
CY (1) CY1112252T1 (de)
DK (1) DK2220492T3 (de)
ES (2) ES2372236T3 (de)
HK (1) HK1213295A1 (de)
HR (1) HRP20110867T1 (de)
IL (1) IL205748A0 (de)
MX (2) MX340668B (de)
NZ (1) NZ628598A (de)
PL (1) PL2220492T3 (de)
PT (1) PT2220492E (de)
RS (1) RS51987B (de)
RU (2) RU2482491C2 (de)
WO (1) WO2009073540A2 (de)
ZA (1) ZA201003419B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102573908B (zh) 2009-10-23 2014-12-17 米伦纽姆医药公司 抗gcc抗体分子及其相关组合物和方法
WO2011146406A1 (en) * 2010-05-17 2011-11-24 University Of Southern California Germline polymorphisms in vegf predict clinical outcomes in cancer patients treated with sorafenib
JP6055764B2 (ja) * 2010-07-19 2016-12-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 乳癌の治療のためのベバシズマブ組合せ療法のための血漿バイオマーカー
WO2012123227A1 (en) * 2011-02-23 2012-09-20 Sanofi Single nucleotide polymorphisms in the promoter of vegfa gene and their use as predictive markers for anti-vegf treatments
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
CN104024431A (zh) * 2011-08-31 2014-09-03 霍夫曼-拉罗奇有限公司 对血管发生抑制剂的响应
ES2589455T3 (es) * 2011-08-31 2016-11-14 F. Hoffmann-La Roche Ag Método para predecir el riesgo de hipertensión asociado a la terapia antiangiogénesis
LT2841575T (lt) * 2012-04-27 2019-10-10 Millennium Pharmaceuticals, Inc. Antikūno molekulės, nukreiptos prieš gcc, ir jų panaudojimas nustatant jautrumą į gcc nukreiptai terapijai
US10456470B2 (en) * 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
KR102581812B1 (ko) 2014-06-18 2023-09-25 국립연구개발법인 고쿠리츠간켄큐센터 폐암의 검출 키트 또는 디바이스 및 검출 방법
JP6685276B2 (ja) 2014-07-18 2020-04-22 サノフイＳａｎｏｆｉ 癌に罹患していることが疑われる患者のアフリベルセプトを用いた処置の結果を予測するための方法
EP3244679B1 (de) * 2015-01-29 2020-02-26 Huawei Technologies Co., Ltd. Funkträgerrekonfigurationsverfahren, verbindungsaufbauverfahren, benutzergerät und basisstation
AU2019269739B2 (en) * 2018-05-18 2025-12-18 Anavex Life Sciences Corp. Optimized sigma-1 agonist method of responder selection and treatment
CN108913772B (zh) * 2018-06-15 2020-04-03 上海思路迪生物医学科技有限公司 基于捕获测序的bMSI检测技术
GR1009959B (el) * 2019-06-21 2021-03-18 ΕΝΟΡΑΣΙΣ ΑΝΩΝΥΜΗ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΚΑΙ ΙΑΤΡΙΚΩΝ ΥΛΙΚΩΝ ΚΑΙ ΜΗΧΑΝΗΜΑΤΩΝ με δ.τ. "ΕΝΟΡΑΣΙΣ Α.Ε." Οι πολυμορφισμοι σαν προβλεπτικοι παραγοντες στην ανταποκριση στη θεραπεια και τη συνολικη επιβιωση

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4998617A (en) 1986-09-15 1991-03-12 Laura Lupton Inc Facial cosmetic liquid make up kit
US6270961B1 (en) 1987-04-01 2001-08-07 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5952172A (en) 1993-12-10 1999-09-14 California Institute Of Technology Nucleic acid mediated electron transfer
US5968740A (en) 1995-07-24 1999-10-19 Affymetrix, Inc. Method of Identifying a Base in a Nucleic Acid
EP1012342A4 (de) 1997-09-10 2004-07-21 Univ Maryland Verfahren zur amplifizierung von dna- sowie rna-produkten, ausgehend von spaltstücken aufgrund von fehlbasenpaarungen
CA2597247A1 (en) * 2005-02-11 2006-08-17 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
JP2007020563A (ja) * 2005-06-13 2007-02-01 Sutaagen:Kk 糖尿病網膜症発症及び／又は進展リスクの診断方法
RU2287158C1 (ru) * 2005-07-07 2006-11-10 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ" (ГОУ ВПО БГМУ РОСЗДРАВА РОССИИ) Способ прогнозирования развития гипертонической болезни по генетическим факторам риска
US7531172B2 (en) 2005-08-12 2009-05-12 Regeneron Pharmaceuticals, Inc. Methods of treating diseases with a VEGF antagonist
CA2644148A1 (en) * 2006-03-03 2007-09-13 University Of Southern California Angiogenesis pathway gene polymorphisms for therapy selection
WO2007103823A2 (en) * 2006-03-03 2007-09-13 University Of Southern California Genetic markers for predicting disease and treatment outcome

Also Published As

Publication number Publication date
ZA201003419B (en) 2012-09-26
JP2011505145A (ja) 2011-02-24
KR20150080020A (ko) 2015-07-08
EP2220492A2 (de) 2010-08-25
KR20100126651A (ko) 2010-12-02
JP2014094014A (ja) 2014-05-22
RU2635525C2 (ru) 2017-11-13
MX2010005868A (es) 2010-12-21
CN102016579B (zh) 2015-04-08
EP2506010A2 (de) 2012-10-03
EP2506010B1 (de) 2015-06-17
DK2220492T3 (da) 2011-12-12
CA2705792A1 (en) 2009-06-11
RU2010126620A (ru) 2012-01-10
US20110176993A1 (en) 2011-07-21
MX340668B (es) 2016-07-20
CN102016579A (zh) 2011-04-13
HK1153815A1 (en) 2012-04-05
PL2220492T3 (pl) 2012-01-31
PT2220492E (pt) 2011-12-16
AU2008334070A1 (en) 2009-06-11
CY1112252T1 (el) 2015-12-09
WO2009073540A2 (en) 2009-06-11
JP2015171388A (ja) 2015-10-01
RU2013107095A (ru) 2014-08-27
JP5797288B2 (ja) 2015-10-21
RU2482491C2 (ru) 2013-05-20
EP2220492B1 (de) 2011-08-31
RS51987B (sr) 2012-02-29
HK1213295A1 (zh) 2016-06-30
AU2008334070B2 (en) 2015-04-16
BRPI0819018A2 (pt) 2015-05-05
ES2372236T3 (es) 2012-01-17
EP2506010A3 (de) 2013-01-09
KR101651690B1 (ko) 2016-08-26
KR101651796B1 (ko) 2016-08-26
US10031141B2 (en) 2018-07-24
ES2547568T3 (es) 2015-10-07
HRP20110867T1 (hr) 2012-01-31
NZ628598A (en) 2016-09-30
CN104805203A (zh) 2015-07-29
IL205748A0 (en) 2010-11-30
WO2009073540A3 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
ATE522809T1 (de) Vegf-polymorphismen und antiangiogenese-therapie
EA200970695A1 (ru) Способы и нуклеиновые кислоты для анализов нарушений клеточной пролиферации
DE602006018057D1 (de) Substituierte chinolone und verwendungsverfahren
WO2007056457A3 (en) Methods, compositions, and kits for the treatment of medical conditions
EA201790716A1 (ru) Использование панелей мутантных генов fgfr для выявления онкологических пациентов, которые будут поддаваться лечению ингибитором fgfr
FR2969596B1 (fr) Procede de traitement d'eau comprenant au moins une etape aeree et une etape de controle de l'apport en oxygene au cours de l'etape aeree
DK2005162T3 (da) Screeningsmetode
WO2009009587A3 (en) Apoptosis-modulating protein therapy for proliferative disorders and nanoparticles containing the same
PL3689346T3 (pl) 3,6-Dipodstawione sole ksantyliowe do leczenia tauopatii
PL2430452T3 (pl) Diagnoza i leczenie raka w oparciu o genotyp odc1
CL2008001837A1 (es) Uso de compuestos derivados de cinolin-3-carboxamida en el tratamiento de la esquizofrenia.
DE602005027400D1 (de) Il-22 zur behandlung von fettleibigkeit, diabetes, hyperlipidämie, hyperglykämie und insulinresistenz
UA96523U (uk) Спосіб прогнозування зрощення перелому
UA96522U (uk) Спосіб прогнозування зрощення перелому
UA94097U (uk) Спосіб прогнозування незрощення перелому
UA96044U (uk) Спосіб прогнозування зрощення перелому
UA106731U (uk) Спосіб прогнозування зрощення перелому
UA96284U (uk) Спосіб прогнозування зрощення перелому
UA94068U (uk) Спосіб прогнозування незрощення перелому
UA96042U (uk) Спосіб прогнозування зрощення перелому
UA96640U (uk) Спосіб прогнозування зрощення перелому
UA96987U (uk) Спосіб прогнозування зрощення перелому
UA106317U (uk) Спосіб прогнозування зрощення перелому
UA95978U (uk) Спосіб прогнозування зрощення перелому
UA96639U (uk) Спосіб прогнозування зрощення перелому

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2220492

Country of ref document: EP